Business, energy, technology, markets and global industry news from Business News Today

H. Lundbeck A/S

PharmaDeviceNews H. Lundbeck A/S
Lundbeck’s investigational orexin 2 receptor agonist Lu AH69593 has received FDA Fast Track designation as competition intensifies to develop new narcolepsy treatments targeting sleep-wake regulation. Representative image.
Pharma & Biotech

Lundbeck has FDA Fast Track status for Lu AH69593, but can it catch the narcolepsy orexin leaders?

Lundbeck’s Lu AH69593 gains FDA Fast Track status, but its Phase 1 narcolepsy programme enters an increasingly competitive orexin field.

Read More